Monotherapy: Key cause of macrolide-resistant Mycobacterium avium complex disease.

[1]  J. Brożek,et al.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline , 2020, European Respiratory Journal.

[2]  D. Wagner,et al.  Non-tuberculous mycobacterial lung disease in patients with bronchiectasis: perceived risk, severity and guideline adherence in a European physician survey , 2020, BMJ Open Respiratory Research.

[3]  Y. Kang,et al.  Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis , 2019, Respiratory Research.

[4]  T. Welte,et al.  European Respiratory Society guidelines for the management of adult bronchiectasis , 2017, European Respiratory Journal.

[5]  T. Betsuyaku,et al.  Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. , 2016, Annals of the American Thoracic Society.

[6]  S. Shin,et al.  Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease , 2016, Antimicrobial Agents and Chemotherapy.

[7]  R. Gibson,et al.  US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis , 2015, Thorax.

[8]  C. Daley,et al.  The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. , 2012, American journal of respiratory and critical care medicine.

[9]  D. Deshpande,et al.  The Antibiotic Resistance Arrow of Time: Efflux Pump Induction Is a General First Step in the Evolution of Mycobacterial Drug Resistance , 2012, Antimicrobial Agents and Chemotherapy.

[10]  William Girard,et al.  Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. , 2006, American journal of respiratory and critical care medicine.